HES1 and nonpapillary renal cell carcinoma: Considering that the targeted miRNA strategy gives us the innovative treatment opportunities, our current results provide a preclinical evidence showing that NOTCH1/HES1 signaling pathway is an alternative target to suppress ccRCC, and that miR-138–2 has an ability to attenuate NOTCH1/HES1 signaling pathway.